A Data Brief on Medicare-Negotiated Drugs: Eliquis, Ozempic, Rybelsus and Wegovy

This data brief accompanies updates to I-MAK’s Drug Patent Book database,1 which now includes nine of the drug products that formed part of the first Medicare negotiation list under the Inflation Reduction Act, as well as the products Ozempic, Rybelsus, and Wegovy (semaglutide) that have been included in the list of medications selected for the second round of negotiations. In this brief, we focus on the patenting and pricing practices for the products Eliquis and Ozempic, Ryblesus, and Wegovy (semaglutide).